The exact function of ABCA10 and ABCA6 remains to be elucidated [41], but the ABCA3 transporter, similar in terms of amino acid sequences and structural organization to ABCA10 and ABCA6 [41], has been shown to impede the efficacy of rituximab in aggressive B-cell lymphomas, and vincristine, anthracyclines and etopside in acute myeloid leukemia when expressed in high levels [42]. Here, ABCA6 is linked to B-cell non-Hodgkin lymphoma.